Abstract
On 25 May 2022 the UK Supreme Court gave judgment in Competition and Markets Authority v. Flynn Pharma and Pfizer, overturning a Court of Appeal ruling which had held that the Competition and Markets Authority should be protected against adverse costs awards in most appeals against CMA decisions. This article examines the background to the case, summarizes the Supreme Court’s main findings and sets the judgment in its wider policy context, focusing in particular on recent debates about appropriate standards of review of competition authority decisions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
